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A third trial oversight committee:
Functions, benefits and issues
J Athene Lane1,2* , Carrol Gamble3,4*, William J Cragg5,6,7 ,
Doreen Tembo8 and Matthew R Sydes5,6
Abstract
Background/aims: Clinical trial oversight is central to the safety of participants and production of robust data. The
United Kingdom Medical Research Council originally set out an oversight structure comprising three committees in
1998. The first committee, led by the trial team, is hands-on with trial conduct/operations (‘Trial Management Group’)
and essential. The second committee (Data Monitoring Committee), usually completely independent of the trial, reviews
accumulating trial evidence and is used by most later phase trials. The Independent Data Monitoring Committee makes
recommendations to the third oversight committee. The third committee, (‘Trial Steering Committee’), facilitates in-
depth interactions of independent and non-independent trial members and gives broader oversight (blinded to compara-
tive analysis). We investigated the roles and functioning of the third oversight committee with multiple research methods.
We reflect upon these findings to standardise the committee’s remit and operation and to potentially increase its usage.
Methods: We utilised findings from our recent published suite of research on the third oversight committee to
inform guideline revision. In brief, we conducted a survey of 38 United Kingdom–registered Clinical Trials Units,
reviewed a cohort of 264 published trials, observed 8 third oversight committee meetings and interviewed 52 trialists.
We convened an expert panel to discuss third oversight committees. Subsequently, we interviewed nine patient/lay third
committee members and eight committee Chairs.
Results: In the survey, most Clinical Trials Units required a third committee for all their trials (27/38, 71%) with inde-
pendent members (ranging from 1 to 6). In the survey and interviews, the independence of the third committee was val-
ued to make unbiased consideration of Independent Data Monitoring Committee recommendations and to advise on
trial progress, protocol changes and recruitment issues in conjunction with the trial leadership. The third committee
also advised funders and sponsors about trial continuation and represented patients and the public by including lay mem-
bers. Of the cohort of 264 published trials, 144 reported a ‘steering’ committee (55%), but the independence of these
members was not described so these may have been internal Trial Management Groups. Around two thirds of papers
(60%) reported having an Independent Data Monitoring Committee and 26.9% neither a steering nor an Independent
Data Monitoring Committee. However, before revising the third committee charter (Terms of Reference), greater stan-
dardisation is needed around defining member independence, composition, primacy of decision-making, interactions
with other committees and the lifespan.
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Introduction
Oversight is key to ensuring that randomised controlled
trials are conducted according to Good Clinical
Practice,1 thus protecting participant rights, well-being
and safety and ensuring robust trial data. However,
trial oversight varies considerably according to funders,
trial type and between countries. The United Kingdom
(UK) Medical Research Council’s (MRC) guidelines
for Good Clinical Practice, first published in 19982 and
updated in 20173 to include global trials, defines a tri-
partite trial oversight committee structure which is
widely used in academic-led (investigator-led) trials
(Table 1 and Figure 1) funded by the UK government
and charities. The first internal committee is responsi-
ble for trial development, day-to-day conduct and dis-
semination. This is called a ‘Trial Management Group’
in the MRC guidelines (sometimes referred to as a
‘Steering Committee’ or operations group) and is led
by the Chief Investigator. A second established over-
sight committee is the (Independent) Data Monitoring
Committee ((I)DMC)4 which monitors accumulating
safety and, often, efficacy data and is usually
unblinded.5 Research and discussion continues about
(I)DMCs as their role and operation evolves over time,
which also highlights international differences since the
third oversight committee (described below) is not
often included in recent American publications about
the (I)DMC.6–8 In the USA, cardiovascular trials have
a Steering Committee in a clinical trial model devel-
oped by the National Institute of Health which com-
prises the trial leadership who develop the protocol,
lead the trial and publish the results.9 One example is
the Metoprolol CR/XL Randomised Intervention Trial
in Congestive Heart Failure (MERIT-HF) trial with an
International Steering Committee comprising the
International Executive Committee, national coordina-
tors from each participating country and a non-voting
sponsor representative.10 A modified model has been
used for industry-sponsored trials with company
employees or a contract research organisation to over-
see the trial, sometimes without a (I)DMC.9
The third trial oversight committee named ‘Trial
Steering Committee’ by the MRC Guidelines2,3 com-
prises a Chair and a majority of independent members
plus key trial personnel (roles and membership sum-
marised in Table 1).2,3 This third committee reviews the
(I)DMC recommendations blinded to outcome data by
randomised treatment groups (unless required by an
(I)DMC recommendation in exceptional circum-
stances). Here, we utilise our recent published research
on the third oversight committee which identified bene-
fits to trial conduct and by including patient advocacy
to set out the arguments for its wider use. We also iden-
tify current challenges and deliberations in its
operation.
Methods
The MRC Network of Hubs for Trial Methodology
Research investigated the roles and function of this
third oversight committee in trials within a suite of five
published research studies. In brief, we conducted a
survey of 38 UK Clinical Trials Units,11 reviewed an
international cohort of 264 published trials,12 observed
8 UK Trial Steering Committee meetings and inter-
viewed 52 trialists.13 We convened an expert panel of
trialists to review these results and existing guidance for
the third oversight committee as the current charter
had not prevented variance in operationalisation of this
committee.14 Concurrently, guidelines were produced
from the National Institute for Health Research (UK
funder) aimed at improving Patient and Public
Involvement in trial oversight committees.15 The key
findings of these five components are summarised in
Table 2 and underpin our recommendations below.
Results
Role and benefits of a third oversight committee
The third committee’s role is multi-faceted14 and distin-
guished from other committees by its independent
member majority, including the Chair, who are blinded
to comparative analyses (Table 1). This allows unbiased
and informed considerations of (I)DMC recommenda-
tions on behalf of sponsors and/or funders and provi-
sion of advice directly to key trial personnel (e.g. Chief
Investigator). The independent Chair and members
should include clinical, statistical and other relevant
experts.14 Patient and Public Involvement contributors
provide an important voice16 valued by trialists,
although more work is required to optimise their con-
tributions.17 A few of the Trial Management Group
(including the Chief Investigator) should be included in
third committee discussions, thus allowing direct
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interactions of the trial team with independent experts
which is a unique feature of this committee (Table 1).
In our survey and interview research, trialists
described this third committee as a valued ‘critical
friend’,16 advising on data quality, trial eligibility, pro-
blematic recruitment, publications and on data release
requests, also serving as a Data Access Committee
(Table 2).11
However, after viewing comparative data, there are
situations where the (I)DMC should not comment on
aspects of the trial, such as protocol amendments to
change the primary outcome measure, target difference
or analysis approach. In the EcLiPSE trial, an impor-
tant competing risk was identified during the trial with
implications for power.18 The (I)DMC explicitly recog-
nised that their knowledge of interim comparative data
compromised their objectivity, and the internal Trial
Management Group may have had interests in continu-
ing the trial which could have also compromised their
recommendations. Therefore, any objective recommen-
dations about the analysis plan required a third
oversight committee which included independent mem-
bers, critically, here, a statistician. The trial statistical
team developed several analyses options which were
reviewed by the third oversight committee which rec-
ommended retention of the original sample size
calculation.
Input from independent experts is important to give
objectivity, but committees solely comprising indepen-
dent members should only make recommendations, not
decisions,19 as was emphasised within recent (I)DMC
recommendations from the Clinical Trials
Transformation Initiative. A decision-making body
was not proposed by the Initiative, but this could be
fulfilled by the third oversight committee which is not
involved in the day-to-day conduct of the trial. The sur-
vey of UK Clinical Trials Units identified that this
third committee is widely used for phase III trials
(Table 2),11 although the published cohort of trials
showed that evidence of its influence and impact inter-
nationally is less clear, partly due to limited reporting
of its use and variation in nomenclature, independence
Table 1. Three committee trial oversight structure, composition, independence and responsibilities.
Name Typical composition Independence in
membership
Primary responsibilities
Trial Management Group (TMG)
(referred to by some as
‘Steering Committee’)
Chair: Chief Investigator
(trial leadership)
Key clinical input
Trial team (including
operations, statistics,
programmers)
Patient and Public
Involvement contributors
No Ongoing trial conduct and day-
to-day operations
Data Monitoring Committee
(DMC) or Independent Data
Monitoring Committee
(I)DMC)a
Chair: Independent
membera
Statisticiana
Clinician(s)a
Additional expertise as
requireda
Yes, usually all, and
reflected in committee
name
Review accumulating unblinded
comparative safety, efficacy and
other outcome data
Third Oversight Committee
(Trial Steering Committee)
Suggested titles: PICTO
(‘Partially-Independent
Committee for Trial Oversight’)
or SITOC (‘Semi-Independent
Oversight Committee’)
Chair: Independent
membera
Clinician(s)a
Statisticiana
Patient and Public
Involvement contributorsa
Chief Investigator
Trial statistician
Sponsor and/or funding
Partial: majority of
independent members,
including Chair and those
markeda
Oversee trial conduct and
progress
Ensure scientific integrity
Advise on protocol, recruitment
progress, adherence/
contamination, follow-up/
attrition and data quality
Advise funders and sponsors on
trial continuation
Review (I)DMC
recommendations blinded to
comparative data
Facilitate patient/public advocacy
Review new external evidence
relating to trial
Review primary trial
publications
Review data access requests (in
some cases)
aIndependent members.
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and membership (Table 2).12 In contrast, interviews
and the expert trialist panel endorsed the role of the
third committee which is widely used in UK academic
trials (70% of trials had a third committee in the sur-
vey, although not feasible or pilot trials) (Table 2).
Challenges and recommendations for
operationalising the third oversight committee
Revising the three-committee oversight structure gui-
dance based on recent research and experience should
encourage its wider and optimal use. Here, we outline
some current issues and logistical considerations upon
which transparency and consistency are sought:
Membership and independence of members. Responsibility
for appointing the committee may be taken by the
sponsor or funder following recommendations from the
trial team. Whoever determines membership might
potentially infer accountability which could impact on
the committees’ perceived independence. The third
committee provides a unique forum for trial team mem-
bers with in-depth trial-specific knowledge to interact
with expert independent members. However, the status,
number and functions of the non-independent contri-
butors (e.g. Chief Investigator, trial coordinator)
require clarification, particularly ahead of considering
(I)DMC recommendations that may require the com-
mittee to access and review accumulating comparative
results or potentially close the trial. The MRC3 and
National Institute for Health Research guidelines20 rec-
ommend that the majority of members should be inde-
pendent. However, some definitions of ‘independence’
may be too restrictive or impede appointing relevant
members.14,16 Definitions used by journal editors21,22
or previously derived for (I)DMCs19,23 may be instruc-
tive. Independence between the third committee and
(I)DMC members may also be important, for example,
if staff management responsibilities occur between
members of committees.14 Standardisation of mechan-
isms to document and help to define members’ indepen-
dence could be a key development.
Patient and Public Involvement contributors. Although
highly valued, there is a lack of clarity currently about
the roles of patient and public contributors. To
enhance Patient and Public Involvement contributions,
there should be role descriptions prior to appointment,
systematic recruitment, initial training and ongoing
support15 both before to inform and prepare patient
and public contributors, during, to facilitate involve-
ment in what could be complex scientific discussions,
and after meetings to allow for further feedback and
comment. Committee members may also benefit from
awareness of recommended good practice from advi-
sory organisations for Patient and Public Involvement
and engagement.15,24
Primacy in decision-making and relationship with
(I)DMCs. The third oversight committee was originally
established as the decision-making committee,2 but
many trialists currently view it as being advisory to fun-
ders and sponsors.13 It is unclear how much authority
the committee really has because funders and sponsors
can withdraw support without reference to, or in con-
tradiction of, third committee recommendations.13 At
Trials
Unit
DMC: Data 
Monitoring 
Committee
TSC: Trial 
Steering 
Committee
Participating centres
DMC feedback to TSC & TSC 
response to DMC
via Trials Unit
Report from 
Trials Unit
Question & 
Feedback
Trial expert panels
Sponsor/Funder
Report from 
Trials Unit
Question & 
Feedback
TMG: Trial 
Management 
Group
Figure 1. Oversight committee structures including third committee (Trial Steering Committee).
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least12 one UK funder has recently constituted a fourth
oversight committee, with independent members, to
oversee trial progress;25 other funders may have similar
structures. Opinions vary among stakeholders13,14 as to
whom the third oversight committee reports, and with
which groups they communicate, including whether
Table 2. Research on third trial oversight committees.
Research focus Methods Sample Main results
Current UK practice and
experience11
Survey 38 Clinical Trials Units 27 Units required a TSC for all trials (71%)
9 Units used one TSC for multiple trials
(27%), most one per trial (29)
33 Units used terms of reference (87%), 30
based on MRC guidance
Independent members ranged from 1 to 6,
usually statistician (24 units), clinicians (35
units) and PPI (28 units)
Variation in operation, for example, voting
rights, quoracy, duration
TSC reviewed protocol changes, main trial
publications, analysis plan and publication
policy (data sharing at 16 units)
TSC decided on trial continuation for
sponsors/funders
Reporting of remit
and function
Literature review of
trials cohort
264 trials published in
6 months in 2012 in
British Medical Journal,
The Lancet and New
England Journal of
Medicine
UK (161) and USA (50)
trials
TSCs reported in 144 trials (55%), 61 called
TSC, 42 Steering Committee, Steering Group
(14) or Executive Committee (10)
109 of trials with TSC also had (I)DMC (76%)
84 TSCs specified chair, clinical (46), statistics
(29), PPI (39) members but independence
could not be determined
Low reporting standards of constitution,
activity make evaluation and impact on trials
impossible to assess
Roles, relationships and
attributes13,16
Observation and
interviews
8 trials TSCs and TMGs
52 interviewees with
trialists
Independence valued, difficult to
operationalise and define
Patient advocacy role important including
through PPI
Quality assurance role a ‘critical friend’
valued highly
Chair is critical to success with experienced
members
Lack of clarity around roles and
accountability
Changes over time in roles of funders,
sponsors and TSC
Review existing guidance,
role and functions14
Expert panel at two
meetings
7 clinicians, statisticians
and trial methodologists
Supported third committee role, need for
revision and expansion of MRC guidelines.
Complex, challenging, real-life examples
needed to ensure comprehensive
development.
Importance of experienced members and
development of training resources
Issues to clarify: indemnity, lifespan,
operationalisation, data sharing role and
primacy with funders and sponsors
Develop PPI guidance in
oversight roles15
Interviews 9 PPI TSC committee
members and 8 TSC
Chairs
TSC good for PPI to provide fresh
perspective
Role and responsibilities need clarity and role
descriptions
Chair to encourage PPI involvement which
teleconferences may hinder
Ongoing support to PPI members needed
No training provided but could help avoid
‘tokenism’
TSC: Trial Steering Committee; MRC: Medical Research Council; PPI: Patient and Public Involvement; (I)DMC: Independent Data Monitoring
Committee TMG: Trial Management Group (sometimes called ‘Steering Committee’).
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this is determined by the nature of their recommenda-
tions or requests. Clinical Trials Units, which coordi-
nate most UK academic/investigator-led government
or charity-funded trials26 (similar to USA data man-
agement/coordinating centres), can facilitate reporting
between oversight committees. A clearly defined pro-
cess should also exist for managing rare disagreements
between the (I)DMC and the third committee. This
process, which should be documented early in the trial,
should ensure appropriate and timely decision-making,
protect the interests of the trial and prevent unneces-
sary exposure of third committee members to blinded
comparative outcome data.19
Organisation, including ‘umbrella’ committee structures. The
third committee is usually formed prior to recruitment,
may inform protocol development and usually finishes
at publication of main results. If the committee assumes
data access responsibilities (a more recent role)14 or
oversight of access to biological samples, it would
potentially have to continue indefinitely because
requests are more likely after the main publications.
Long-term committee maintenance may become
impractical so requires further consideration and clarity
of duration in the charter.
The third committee’s initial meeting is preferably
held face-to-face early in the trial for members to
become familiar with each other and the trial and to
facilitate future communications; this meeting can be
joint with the (I)DMC to build trust and working rela-
tionships. Subsequently, remote meeting methods (e.g.
videoconference) may enable frequent, quorate meet-
ings, especially with international membership, although
this may reduce members’ ability to contribute effec-
tively, especially Patient and Public Involvement mem-
bers.17 The meeting mode may also be informed by the
nature of the (I)DMC recommendations, and further
work is needed on understanding the impact of the
mode on member input and function.
Reports from the (I)DMC and their rationale must
be sufficiently detailed to allow the third committee to
consider them effectively. Excessive detail, however,
may expose the third committee members to blinded,
undisclosed or inappropriate information which may
compromise their role going forward. Standardised
inter-committee reporting methods (e.g. template docu-
ments) would reduce these potential pitfalls. Updating
relevant external evidence for the committee underpins
the third committee’s ability to provide an informed
broader view of a trial’s continued legitimacy. Literature
reviewing methods should be transparent to guard
against potential bias, for example, a documented search
strategy.
Membership is usually voluntary and trialists report
difficulties in getting experienced members.11
Convening a third committee that oversees multiple
trials in a clinical area ( ‘umbrella committee’) could be
time and resource efficient but might be challenged by
time constraints to give adequate oversight of complex
trials or those in difficulties.16 A wider variety of trials,
requiring further expertise, may also be difficult to
encompass in one committee. Umbrella committees
may reduce scheduling issues but have increased risk of
(future) conflicts of interest. Agreeing independent
membership may also be difficult across multiple fun-
ders and sponsors. This promising approach to trial
research efficiency requires more formal evaluation.
Conclusion
Robust clinical trial oversight is critical to the validity
and safety of trials, but some roles are less suited to
internal management groups or an independent DMC.
We identified that a third oversight committee gives
additional independent guidance and an expert inter-
face between independent and trial members, is valued
by trialists and incorporates patient and public contri-
butors. This third committee is used widely in UK
academic-led trials and prevents recommendations
from the (I)DMC being considered solely by the trial
team. Some issues still exist for operationalising this
third committee optimally, and their resolution through
wider engagement could result in internationally recog-
nised trial oversight standards.
We anticipate that a clearer oversight structure
should benefit academic-led and industry-led trials,
especially later-phase trials. We propose ‘PICTO:
Partly-Independent Committee for Trial Oversight’ or
‘SITOC: Semi-Independent Trial Oversight Committee’
to emphasise the independence of the Chair and some
members and to distinguish it from the internal Trial
Management Group (sometimes called a ‘steering com-
mittee’). We also propose that (I)DMCs should make
recommendations directly to the third committee.23
There is widespread utilisation of data monitoring
charters19 for the (I)DMC, and agreement on a third
oversight committee charter would delineate the com-
mittee purpose and functions more clearly and poten-
tially increase its uptake and value.
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